NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Clinical trial NCT05664217 · TERMINATED

Trial details

NCT number: NCT05664217
Sponsor: Nektar Therapeutics
Status: TERMINATED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Non-Hodgkin Lymphoma Relapsed/Refractory Diffuse Large B-cell Lymphoma

Start date: 2022-12-23
Primary completion: 2024-05-22
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.